Immune-Related Adverse Events from Checkpoint Inhibitors: Mechanisms, Monitoring, and Graded Management

Mechanisms of irAE Pathogenesis

Immune checkpoint inhibitors (ICIs)—including CTLA-4 inhibitors (ipilimumab), PD-1 inhibitors (nivolumab, pembrolizumab), and PD-L1 inhibitors (atezolizumab, durvalumab, avelumab)—disrupt immune tolerance through multiple interconnected mechanisms1.

T-cell-mediated autoimmunity forms the primary pathogenic basis. Genetic loss-of-function studies in mice and human observations support central T-cell involvement: shared T-cell clones have been identified across tumor tissue, heart, and skeletal muscle in melanoma patients who died from fatal myocarditis and myositis after anti-CTLA-4/PD-1 combination therapy1. CTLA-4 blockade modulates regulatory T cells (Tregs) and tissue-resident memory T cells, while PD-1/PD-L1 inhibition releases peripheral tolerance checkpoints, permitting cross-reactive T-cell responses against shared tumor and self-antigens1.

Humoral immunity operates through organ-specific autoantibodies. Anti-thyroglobulin (anti-TG) and anti-thyroid peroxidase (anti-TPO) antibodies associate with thyroid dysfunction; anti-GNAL and anti-ITM2B with hypophysitis; anti-acetylcholine receptor with ICI-myasthenia gravis; and anti-BP180 with bullous pemphigoid1. Critically, baseline autoantibodies can predict specific irAEs: thyroid autoantibodies predict thyroid dysfunction, and pancreatic islet antibodies associate with ICI-induced diabetes1.

Cytokine and chemokine dysregulation drives systemic inflammation. Baseline IL-17 associates with subsequent colitis; elevated IL-6/IL-10 with skin irAEs; higher baseline IL-1β, IL-2, and GM-CSF with thyroid dysfunction; and elevated CXCL9/CXCL10 with irAEs generally1. In severe colitis from combination therapy, IL-1β upregulation has been documented1.

Genetic predisposition involves HLA alleles: HLA-DR4 associates with ICI-induced diabetes and arthritis; HLA-DRB1*04:05 with arthritis specifically; and polygenic risk scores link to thyroid and dermatologic irAEs1. Microbiome composition influences both tumor response and toxicity risk. Taxa such as Faecalibacterium, Firmicutes, and Bacteroides intestinalis correlate with survival and colitis risk; fecal microbiota transplant (FMT) data suggest microbiome signatures relate to checkpoint inhibitor combination therapy-associated intestinal damage1.

Risk modifiers include ICI class (CTLA-4 inhibitors and combination regimens carry higher toxicity rates than PD-1/PD-L1 monotherapy)15, pre-existing autoimmune disease (which accelerates irAE onset)1, high tumor burden (associated with severe irAEs in non-small-cell lung cancer)1, and concomitant medications19.

Clinical Spectrum and Temporal Patterns

irAEs occur in 65–76% of patients at all severity grades, with 3–5% presenting as grade 3 or higher12. Although most toxicities are mild and reversible, 0.3–1.3% are severe and potentially fatal12.

Fatal irAEs predominantly involve myocarditis, colitis, and pneumonitis, with fatality rates higher in combination therapy1. Myocarditis has an incidence of 0.27–1.14% but carries significant mortality risk1. Troponin elevation, ECG changes, and cardiac MRI findings are common; patients with concurrent myocarditis, myositis, and myasthenia gravis have particularly poor prognosis113.

Gastrointestinal toxicity manifests as diarrhea (most frequent) and colitis. Incidence ranges from 1–25% depending on ICI type, with colitis more common with ipilimumab (up to 30%) and combination therapy (32%) than anti-PD-1/PD-L1 monotherapy (9%)25. Onset occurs earlier with combination therapy (median 40 days) versus monotherapy (median 68 days)2. Approximately one-third to two-thirds of colitis cases prove steroid-refractory, requiring infliximab or vedolizumab511.

Hepatic irAEs occur at 3–9% with anti-CTLA-4, 0.7–1.8% with anti-PD-1/PD-L1, and 29% (17% high-grade) with combination therapy1. Autoantibodies are common in ICI-associated hepatitis1.

Endocrine irAEs present distinct patterns417. Thyroiditis (most common, onset ~6 weeks) typically manifests as initial hyperthyroidism followed by hypothyroidism; anti-inflammatory glucocorticoids have minimal therapeutic role, and hormone replacement is primary management14. Hypophysitis occurs especially with ipilimumab (3.2% monotherapy, 6.4% combination)12; steroids often do not reverse pituitary damage, necessitating lifelong hormone replacement1. PD-1 blockade-induced diabetes often presents with diabetic ketoacidosis, is HLA-DR4-associated, and usually permanent117.

Pneumonitis incidence approximates 3–5% in trials but reaches 13–19% in real-world data, with consistent grade ≥3 rates1. Renal irAEs (usually acute interstitial nephritis) are rare but serious, with higher incidence in combination therapy1.

Monitoring Strategies: A Three-Phase Approach

Chinese consensus guidelines emphasize that time from symptom onset to hormone initiation correlates with patient prognosis, with door-to-steroid time <12 hours recommended for severe toxicity12. The first hour after severe toxicity onset is critical12.

Baseline Risk Assessment

For high-risk populations, comprehensive baseline evaluation should include history and physical examination, laboratory tests (complete blood count, comprehensive metabolic panel including liver function tests, coagulation panel, cardiac enzymes, urinalysis, stool analysis, inflammatory markers), infectious disease screening (hepatitis B/C, HIV, syphilis, tuberculosis, COVID-19), and autoantibody screening (antinuclear antibodies, antineutrophil cytoplasmic antibodies, rheumatoid factor)12. Organ-specific assessments—renal function, thyroid function tests (TSH, free T4), adrenal function, lung function, cardiac assessment, and skin/musculoskeletal examination—are recommended based on individual risk factors12.

On-Treatment Monitoring

Monitoring frequency is generally every 2–4 weeks during ICI therapy, with increased frequency in the first 4 months12. For high-risk patients and those with treatment abnormalities, comprehensive evaluation every 1–2 cycles is recommended12. After 4 months without toxicity, evaluation frequency may decrease12. Specific monitoring includes clinical symptom inquiry and physical examination before each treatment, general laboratory tests at regular intervals, and organ-specific imaging or testing when abnormalities are detected12.

For renal monitoring, the 2025 Chinese expert consensus recommends weekly grading reassessment when renal irAE is suspected12. Thyroid function monitoring should occur at baseline and periodically during treatment given high incidence14.

Biomarker-Guided Surveillance

Baseline autoantibodies predict specific irAEs: thyroid antibodies predict thyroid dysfunction; pancreatic islet autoantibodies associate with ICI-induced diabetes1. Dynamic biomarkers include troponin and ECG for cardiac toxicity113, liver enzymes for hepatitis1, and peripheral blood signatures such as activated CD4 memory T cells and T-cell receptor diversity linking to severe irAEs1. However, C-reactive protein, albumin, and hemoglobin did not correlate with irAE colitis severity in one dual-center study, possibly reflecting that the ICI patient population is older and more comorbid than typical inflammatory bowel disease patients2.

Graded Management Principles: CTCAE-Based Algorithms

Glucocorticoids represent the mainstay of irAE management, though other immunosuppressive drugs are used for refractory cases1. Management follows a severity-graded approach aligned with Common Terminology Criteria for Adverse Events (CTCAE).

General Treatment Framework

Grade 1 irAEs: ICI continuation is generally permitted with enhanced monitoring and symptomatic management. Weekly organ function reassessment is recommended for renal irAE12. For mild asymptomatic amylase/lipase elevation, ICI may continue after excluding other causes12.

Grade 2 irAEs: ICI should be paused12. Initial corticosteroid dosing of prednisone or equivalent 0.5–1.0 mg/kg/day is recommended12. For renal irAE, this includes cases where serum creatinine remains ≥2.0× baseline or ≥1.5× upper limit of normal after excluding other factors, or when urine protein exceeds 1 g/day12. Treatment should begin early (within 2 weeks of diagnosis)12. Organ function should be rechecked every 3–5 days12.

Grade 3 irAEs: ICI discontinuation is required, with IV methylprednisolone 1–2 mg/kg/day12. Monitoring intensifies to every 1–2 days for hepatitis12. After declining to Grade 2, conversion to equivalent oral prednisone with gradual tapering follows12. For severe presentations such as acute progressive glomerulonephritis, methylprednisolone pulse therapy (0.5–1.0 g/day IV for 3 days) is recommended12.

Grade 4 irAEs: Permanent ICI discontinuation with immediate IV methylprednisolone 1–2 mg/kg/day, hospitalization, and daily monitoring12. All Grade 4 patients permanently discontinue ICIs except for endocrinopathies manageable with hormone replacement12.

However, CTCAE grading shows important limitations. A dual-center retrospective study of 134 patients with irAE colitis found that CTCAE diarrhea grade did not correlate with steroid or infliximab use, and colitis grade showed limited predictive value2. CTCAE assessment does not accurately reflect colitis severity and should not be used in isolation, as this may negatively impact timely management2.

Organ-Specific Management

Colitis: For Grade 2 or higher, corticosteroids are recommended while holding immunotherapy5. If no improvement or worsening within 2–3 days on oral prednisone 1 mg/kg/day, escalation to 2 mg/kg/day and consideration of infliximab or vedolizumab is advised12. Endoscopic assessment provides superior prognostic value: both Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo scores correlated with severity and infliximab requirement (p=0.008 and p=0.016, respectively), with erosions most strongly associated with infliximab need (odds ratio 7.0; p=0.01)2. Histological severity (Nancy index 3/4) also predicted infliximab requirement (p=0.03)2. Steroid-refractory cases benefit from infliximab; vedolizumab proves efficacious in steroid- and infliximab-refractory cases511.

Hepatitis: Mycophenolate mofetil (500–1000 mg twice daily) should be added for Grade 3 or higher hepatitis unresponsive to IV corticosteroids after 3 days12. Infliximab is not recommended due to potential hepatic toxicity1216. Other treatments for steroid-refractory acute fulminant hepatitis include antithymocyte globulin, plasma exchange, IL-6 monoclonal antibody, and CD20 monoclonal antibody12.

Pneumonitis: Grade 3 or higher requires ICU admission, bronchoscopy/bronchoalveolar lavage, and high-dose IV corticosteroids (methylprednisolone 1–4 mg/kg/day or equivalent)12. For patients unresponsive after 2 days, adding immunosuppressants (infliximab, mycophenolate mofetil, or cyclophosphamide) is recommended12. Guidelines recommend very slow, cautious tapering over 4–8 weeks12.

Myocarditis: Suspected severe myocarditis requires immediate methylprednisolone pulse (1 g/day for 3–5 days)12. If no improvement at 24 hours, consider IV immunoglobulin, antithymocyte globulin, IL-6 receptor inhibitor, or infliximab (noting infliximab association with heart failure—contraindicated in moderate-severe heart failure)12. Abatacept and alemtuzumab have been reported in case scenarios1. Patients with ICI-induced myasthenia gravis should be screened and monitored for myocarditis, a potentially fatal complication13.

Endocrinopathies: For suspected acute ACTH deficiency, blood sampling for cortisol/ACTH should occur immediately without awaiting results, with concurrent IV hydrocortisone 100 mg infusion beginning, followed by 100 mg IV every 8 hours12. Supraphysiologic corticosteroid therapy compared to replacement dosing does not better improve symptoms or shorten pituitary function recovery and increases infection/hyperglycemia risk12. Physiologic replacement represents daily cortisol generation of 5–10 mg/m² body surface area12. ICI continuation is permitted for most endocrinopathies with appropriate hormone replacement412.

Renal irAE: For Grade 3 or higher, or concurrent glomerular disease or vasculitis, or poor corticosteroid response, immunosuppressive agents should be considered12. Mycophenolate mofetil is most commonly used for interstitial nephritis, followed by infliximab12. For oligoimmune complex glomerulonephritis and renal vasculitis, cyclophosphamide or rituximab combination use is recommended12.

Tocilizumab for Steroid-Refractory irAEs

A single-center study of 87 patients treated with nivolumab found that 34 (39.1%) required tocilizumab (4 mg/kg IV) while on corticosteroids for Grade 3/4 irAEs including pneumonitis (35.3%), serum sickness/systemic inflammatory response syndrome (35.3%), and cerebritis (14.7%)3. Clinical improvement occurred in 79.4% of patients, with median hospital discharge at 4 days3. C-reactive protein showed statistically significant decline after tocilizumab (p<0.00001)3. However, randomized trials are needed to better elucidate relative efficacy and safety3.

Corticosteroid Tapering and Prophylaxis

Gradual tapering typically occurs over 4–6 weeks or longer for some organ toxicities1. Chinese guidelines recommend total corticosteroid therapy duration of 12–24 weeks adjusted according to organ pathology for renal irAE12. For high-dose corticosteroids (1–2 mg/kg/day), especially pulse therapy or in patients with gastrointestinal hemorrhage risk, consider proton pump inhibitor or H2 antagonist prophylaxis12. For prednisone ≥20 mg/day for ≥4 weeks, consider Pneumocystis jirovecii pneumonia prophylaxis; for prolonged courses (prednisone >20 mg/day for ≥6–8 weeks), consider in selected high-risk patients (e.g., additional immunosuppression, prior fungal disease, profound lymphopenia)12.

Rechallenge Considerations and Long-Term Sequelae

ICI rechallenge decisions depend on initial irAE severity. For Grade 3 or higher renal irAE, ICI rechallenge is not recommended; Grade 2 requires careful consideration; Grade 1 may be considered for rechallenge12. Severe vasculitis or glomerular disease presentations should avoid ICI rechallenge12.

After renal function recovery, 22.5–25.0% of ICI-acute kidney injury patients experience recurrent injury upon ICI rechallenge, with 16.5% representing ICI-related acute kidney injury, mostly occurring ~10 weeks after rechallenge12. When reinitiating ICI therapy, concurrent low-dose corticosteroids (prednisone 10 mg/day) may reduce irAE recurrence risk12.

Resuming ICIs after colitis resolution carries a manageable risk of recurrent diarrhea and colitis, with most cases being mild and effectively managed with immunosuppressive therapy7. In Grade 4 colitis, immunotherapy is permanently discontinued; the decision is controversial in Grade 3 colitis5.

Long-Term Outcomes and Chronic irAEs

ICI-associated endocrinopathies typically cause permanent hormone deficiency necessitating long-term management and patient engagement4. ICI-induced hypothyroidism recovery is partial with ICI discontinuation12. PD-1 blockade-induced diabetes is usually permanent1. Hypophysitis often results in permanent pituitary dysfunction despite treatment14.

For renal irAE, recovery rates correlate with initial acute kidney injury grade: Grade 1 AKI ~90.9%, Grade 2 ~70.8%, Grade 3 ~50.0%12. In an 85-case meta-analysis of ICI-acute tubulointerstitial nephritis, 40.0% achieved complete recovery, 56.2% partial recovery, and only 3.8% no recovery12. ICI-associated glomerular disease patients have poor prognosis: only 30.6% achieved complete renal recovery, 41.7% partial recovery, and 19.4% remained dialysis-dependent12.

ICI-thyroiditis has been associated with improved survival, while other endocrinopathies have not shown significant association with cancer outcomes in ICI-treated patients4. Multidisciplinary oncoendocrinology teams can improve care of patients with ICI-associated endocrinopathies4.

Summary Table: Common irAEs by Organ System

Abbreviations: ACTH, adrenocorticotropic hormone; AChR, acetylcholine receptor; ATG, antithymocyte globulin; BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; CT, computed tomography; ECG, electrocardiogram; EMG, electromyography; ICI, immune checkpoint inhibitor; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; MRI, magnetic resonance imaging; TSH, thyroid-stimulating hormone; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

Conclusion: Effective irAE management requires mechanistic understanding, vigilant multidisciplinary monitoring, prompt CTCAE-graded intervention with corticosteroids as first-line therapy, and readiness to escalate to organ-specific immunosuppressive agents for steroid-refractory cases. Early recognition and treatment—ideally door-to-steroid time <12 hours for severe toxicities—significantly improve outcomes. Endoscopic and histologic scoring outperforms CTCAE grading for predicting colitis severity and treatment response. Rechallenge requires individualized risk-benefit assessment, with Grade 3–4 irAEs generally contraindicating ICI resumption except for hormone-replaceable endocrinopathies. Emerging strategies including tocilizumab, fecal microbiota transplantation, and biomarker-guided monitoring warrant ongoing investigation12371012.